# Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

> **NCT01176474** · PHASE1 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 73 (actual)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** NY-ESO-1 157-165 (165V)
- **DRUG:** Nivolumab
- **BIOLOGICAL:** gp100:280-288 (288V)
- **DRUG:** Montanide ISA 51 vegetable grade (VG)
- **DRUG:** Ipilimumab
- **PROCEDURE:** Apheresis Procedure

## Key facts

- **NCT ID:** NCT01176474
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08-13
- **Primary completion:** 2020-08
- **Final completion:** 2023-01-06
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2023-07-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01176474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01176474, "Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01176474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*